Development of PSMA-Targeted Alpha Therapy Using [²¹¹At]PSMA-5

Watabe, Tadashi; Naka, Sadahiro; Shirakami, Yoshifumi; Kaneda, Kazuko; Murakami, Masashi; Toyoshima, Atsushi; Cardinale, Jens; Giesel, Frederik L.

doi:https://doi.org/10.1053/j.semnuclmed.2025.09.005

Development of PSMA-Targeted Alpha Therapy Using [²¹¹At]PSMA-5

Watabe, Tadashi; Naka, Sadahiro; Shirakami, Yoshifumi et al.

Seminars in Nuclear Medicine, 2025, 55(6), 947-954

Number of Access:65（2025-12-18 20:37 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/103291

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
SeminNuclMed_55_6_947	pdf	None	2.03 MB	13	2025.12.02

Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Development of PSMA-Targeted Alpha Therapy Using [²¹¹At]PSMA-5
Creator	NRID 1000090648932 1000090648932 ORCID 0000-0001-8658-2395 0000-0001-8658-2395 researchmap permalink twosaka2018 twosaka2018 Scopus Author ID 57421862900 57421862900 CreatorName Watabe, Tadashi
	NRID 1000060599843 1000060599843 researchmap permalink _sada_ _sada_ CreatorName Naka, Sadahiro
	NRID 1000000560400 1000000560400 ORCID 0000-0003-2352-9057 0000-0003-2352-9057 researchmap permalink e5221 e5221 Scopus Author ID 6603428576 6603428576 CreatorName Shirakami, Yoshifumi
	NRID 1000000533209 1000000533209 ORCID 0000-0001-6657-5059 0000-0001-6657-5059 researchmap permalink read0131912 read0131912 CreatorName Kaneda, Kazuko
	ORCID 0000-0001-7936-2263 0000-0001-7936-2263 researchmap permalink murakami-masashi murakami-masashi Scopus Author ID 55378274900 55378274900 CreatorName Murakami, Masashi
	NRID 1000040414578 1000040414578 researchmap permalink read0076538 read0076538 Scopus Author ID 15833301700 15833301700 CreatorName Toyoshima, Atsushi
	CreatorName Cardinale, Jens
	CreatorName Giesel, Frederik L.
Description	Watabe T., Naka S., Shirakami Y., et al. Development of PSMA-Targeted Alpha Therapy Using [²¹¹At]PSMA-5. Seminars in Nuclear Medicine 55, 947 (2025); https://doi.org/10.1053/j.semnuclmed.2025.09.005.
Abstract	Astatine (²¹¹At) is an alpha-emitting nuclide with a 7.2-hour half-life that can be produced using a 30-MeV cyclotron. In recent years, the number of production sites worldwide has been increasing, attracting growing attention to ²¹¹At. We have developed a novel ²¹¹At-labeled PSMA-targeted agent ([²¹¹At]PSMA-5). After conducting preclinical evaluations of its antitumor efficacy and safety, we initiated a first-in-human, investigator-initiated clinical trial in patients with metastatic castration-resistant prostate cancer. To date, the drug has been administered to a total of nine patients, and we have reported high accumulation of [²¹¹At]PSMA-5 in recurrent and metastatic lesions. While further efforts are required for the social implementation of ²¹¹At-based targeted alpha therapy, including the establishment of a supply chain and the accumulation of additional clinical evidence, PSMA-targeted alpha therapy using ²¹¹At represents a promising treatment modality owing to its cyclotron-based production, sustainability, and clean decay characteristics.
Publisher	W.B. Saunders
Source Title	Seminars in Nuclear Medicine
Volume (Issue)	55(6)
Page	947-954
Date of Issued	2025-10-24
Language	English
Handle URL	https://hdl.handle.net/11094/103291
PISSN	00012998
eISSN	15584623
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1053/j.semnuclmed.2025.09.005
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Seminars in Nuclear Medicine. 2025, 55(6), p. 947-954
DC.title	Development of PSMA-Targeted Alpha Therapy Using [²¹¹At]PSMA-5
DC.creator	Watabe, Tadashi
	Naka, Sadahiro
	Shirakami, Yoshifumi
	Kaneda, Kazuko
	Murakami, Masashi
	Toyoshima, Atsushi
	Cardinale, Jens
	Giesel, Frederik L.
DC.publisher	W.B. Saunders
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2025-10-24
DC.identifier	https://doi.org/10.1053/j.semnuclmed.2025.09.005
DC.description	Watabe T., Naka S., Shirakami Y., et al. Development of PSMA-Targeted Alpha Therapy Using [²¹¹At]PSMA-5. Seminars in Nuclear Medicine 55, 947 (2025); https://doi.org/10.1053/j.semnuclmed.2025.09.005.
DCTERMS.abstract	Astatine (²¹¹At) is an alpha-emitting nuclide with a 7.2-hour half-life that can be produced using a 30-MeV cyclotron. In recent years, the number of production sites worldwide has been increasing, attracting growing attention to ²¹¹At. We have developed a novel ²¹¹At-labeled PSMA-targeted agent ([²¹¹At]PSMA-5). After conducting preclinical evaluations of its antitumor efficacy and safety, we initiated a first-in-human, investigator-initiated clinical trial in patients with metastatic castration-resistant prostate cancer. To date, the drug has been administered to a total of nine patients, and we have reported high accumulation of [²¹¹At]PSMA-5 in recurrent and metastatic lesions. While further efforts are required for the social implementation of ²¹¹At-based targeted alpha therapy, including the establishment of a supply chain and the accumulation of additional clinical evidence, PSMA-targeted alpha therapy using ²¹¹At represents a promising treatment modality owing to its cyclotron-based production, sustainability, and clean decay characteristics.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	103291
citation_title	Development of PSMA-Targeted Alpha Therapy Using [²¹¹At]PSMA-5
citation_author	Watabe, Tadashi
	Naka, Sadahiro
	Shirakami, Yoshifumi
	Kaneda, Kazuko
	Murakami, Masashi
	Toyoshima, Atsushi
	Cardinale, Jens
	Giesel, Frederik L.
citation_publisher	W.B. Saunders
citation_language	English
citation_date	2025-10-24
citation_journal_title	Seminars in Nuclear Medicine
citation_volume	55
citation_issue	6
citation_firstpage	947
citation_lastpage	954
citation_doi	https://doi.org/10.1053/j.semnuclmed.2025.09.005
citation_public_url	https://hdl.handle.net/11094/103291

Development of PSMA-Targeted Alpha Therapy Using [²¹¹At]PSMA-5

Link to primary information

Item Information

Show details